Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-18T21:06:32.313Z Has data issue: false hasContentIssue false

Proinflammatory cytokine levels in patients with conversion disorder

Published online by Cambridge University Press:  21 February 2013

Utkan Tiyekli*
Affiliation:
Department of Psychiatry, Trakya University Hospital, Edirne, Turkey; Department of Psychiatry, Oltu State Hospital, Oltu, Erzurum, Turkey;
Okan Çalıyurt
Affiliation:
Department of Psychiatry, Trakya University Hospital, Edirne, Turkey;
Nimet Dilek Tiyekli
Affiliation:
Department of Immunology, Trakya University Hospital, Edirne, Turkey
*
Department of Psychiatry, Oltu State Hospital, postal code 25400, Oltu, Erzurum, Turkey. Tel: +90 530 2921575; Fax: +90 442 8165258; E‐mail: [email protected]

Abstract

Objective

It was aimed to evaluate the relationship between proinflammatory cytokine levels and conversion disorder both commonly known as stress regulated.

Method

Baseline proinflammatory cytokine levels–[Tumour necrosis factor alpha (TNF‐α), Interleukin‐1 beta (IL‐1β), Interleukin‐6 (IL‐6)]–were evaluated with enzyme‐linked immunosorbent assay in 35 conversion disorder patients and 30 healthy controls. Possible changes in proinflammatory cytokine levels were evaluated again, after their acute phase in conversion disorder patients.

Results

Statistically significant decreased serum TNF‐α levels were obtained in acute phase of conversion disorder. Those levels increased after acute conversion phase. There were no statistically significant difference observed between groups in serum IL‐1β and (IL‐6) levels.

Conclusions

Stress associated with conversion disorder may suppress immune function in acute conversion phase and may have diagnostic and therapeutic value.

Type
Original Articles
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

All authors have contributed equally to the manuscript.

References

1Flor‐Henry, P, Fromm‐Auch, D, Tapper, M et al. A neuropsychological study of the stable syndrome of hysteria. Biol Psychiatry 1981;16:601626.Google Scholar
2Sackeim, HA, Nordlie, JW, Gur, RC. A model of hysterical and hypnotic blindness: cognition, motivation, and awareness. J Abnorm Psychol 1979;88:474489.Google Scholar
3American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM‐IV‐TR. 4edn. Washington, DC: American Psychiatric Press, 1994.Google Scholar
4American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM‐III. Washington, DC: American Psychiatric Press, 1980.Google Scholar
5World Health Organization. The ICD‐10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.Google Scholar
6Mayou, R, Levenson, J, Sharpe, M. Somatoform disorders in DSM‐V. Psychosomatics 2003;44:449451.Google Scholar
7Mayou, R, Kirmayer, LJ, Simon, G et al. Somatoform disorders: time for a new approach in DSM‐V. Am J Psychiatry 2005;162:847855.Google Scholar
8Brown, RJ, Cardena, E, Nijenhuis, E et al. Should conversion disorder be reclassified as a dissociative disorder in DSM V? Psychosomatics 2007;48:369378.Google Scholar
9Nijenhuis, ER, Spinhoven, P, Van, DR et al. Degree of somatoform and psychological dissociation in dissociative disorder is correlated with reported trauma. J Trauma Stress 1998;11:711730.Google Scholar
10Kisiel, CL, Lyons, JS. Dissociation as a mediator of psychopathology among sexually abused children and adolescents. Am J Psychiatry 2001;158:10341039.Google Scholar
11Chu, JA, Dill, DL. Dissociative symptoms in relation to childhood physical and sexual abuse. Am J Psychiatry 1990;147:887892.Google Scholar
12Sar, V, Akyuz, G, Kundakci, T et al. Childhood trauma, dissociation, and psychiatric comorbidity in patients with conversion disorder. Am J Psychiatry 2004;161:22712276.Google Scholar
13Marshall, JC, Halligan, PW, Fink, GR et al. The functional anatomy of a hysterical paralysis. Cognition 1997;64:B1B8.Google Scholar
14Spence, SA, Crimlisk, HL, Cope, H et al. Discrete neurophysiological correlates in prefrontal cortex during hysterical and feigned disorder of movement. Lancet 2000;355:12431244.Google Scholar
15Vuilleumier, P, Chicherio, C, Assal, F et al. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain 2001;124:10771090.Google Scholar
16Tiihonen, J, Kuikka, J, Viinamaki, H et al. Altered cerebral blood flow during hysterical paresthesia. Biol Psychiatry 1995;37:134135.Google Scholar
17Yazici, KM, Kostakoglu, L. Cerebral blood flow changes in patients with conversion disorder. Psychiatry Res 1998;83:163168.Google Scholar
18Mailis‐Gagnon, A, Giannoylis, I, Downar, J et al. Altered central somatosensory processing in chronic pain patients with ‘hysterical’ anesthesia. Neurology 2003;60:15011507.Google Scholar
19Werring, DJ, Weston, L, Bullmore, ET et al. Functional magnetic resonance imaging of the cerebral response to visual stimulation in medically unexplained visual loss. Psychol Med 2004;34:583589.Google Scholar
20Harvey, SB, Stanton, BR, David, AS. Conversion disorder: towards a neurobiological understanding. Neuropsychiatr Dis Treat 2006;2:1320.Google Scholar
21Ron, M. Explaining the unexplained: understanding hysteria. Brain 2001;124:10651066.Google Scholar
22Ader, R. On the development of psychoneuroimmunology. Eur J Pharmacol 2000;405:167176.Google Scholar
23Ader, R, Cohen, N. Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol 1993;44:5385.Google Scholar
24Ziemssen, T, Kern, S. Psychoneuroimmunology–cross‐talk between the immune and nervous systems. J Neurol 2007;254(Suppl. 2):II8II11.Google Scholar
25Irwin, MR. Human psychoneuroimmunology: 20 years of discovery. Brain Behav Immun 2008;22:129139.Google Scholar
26Schiepers, OJ, Wichers, MC, Maes, M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201217.Google Scholar
27Marques, AH, Cizza, G, Sternberg, E. Brain‐immune interactions and implications in psychiatric disorders. Rev Bras Psiquiatr 2007;29(Suppl. 1):S27S32.Google Scholar
28Kilicoglu, A. Stres ve Beyindeki Etkileri: Bir Gözden Geçirme. Yeni Symposium Journal 2007;45:134138.Google Scholar
29Bear, MF, Connors, BW, Paradiso, MA. Neuroscience exploring the brain. Philadelphia: Lippincott Williams and Wilkins, 2001.Google Scholar
30McEwen, BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000;886:172189.Google Scholar
31Steinman, L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004;5:575581.Google Scholar
32Lechan, RM, Toni, R, Clark, BD et al. Immunoreactive interleukin‐1 beta localization in the rat forebrain. Brain Res 1990;514:135140.Google Scholar
33Chrousos, GP. The hypothalamic‐pituitary‐adrenal axis and immune‐mediated inflammation. N Engl J Med 1995;332:13511362.Google Scholar
34Irwin, M, Jones, L, Britton, K et al. Central corticotropin releasing factor reduces natural cytotoxicity. Time course of action. Neuropsychopharmacology 1989;2:281284.Google Scholar
35Strausbaugh, H, Irwin, M. Central corticotropin‐releasing hormone reduces cellular immunity. Brain Behav Immun 1992;6:1117.Google Scholar
36Irwin, MR, Vale, W, Britton, KT. Central corticotropin‐releasing factor suppresses natural killer cytotoxicity. Brain Behav Immun 1987;1:8187.Google Scholar
37Agarwal, SK, Marshall, GD Jr. Stress effects on immunity and its application to clinical immunology. Clin Exp Allergy 2001;31:2531.Google Scholar
38Zavala, F. Benzodiazepines, anxiety and immunity. Pharmacol Ther 1997;75:199216.Google Scholar
39Irwin, M, Hauger, RL, Britton, K. Benzodiazepines antagonize central corticotropin releasing hormone‐induced suppression of natural killer cell activity. Brain Res 1993;631:114118.Google Scholar
40Sheridan, JF, Dobbs, C, Jung, J et al. Stress‐induced neuroendocrine modulation of viral pathogenesis and immunity. Ann N Y Acad Sci 1998;840:803808.Google Scholar
41Amkraut, AA, Solomon, GF, Kraemer, HC. Stress, early experience and adjuvant‐induced arthritis in the rat. Psychosom Med 1971;33:203214.Google Scholar
42Padgett, DA, Sheridan, JF, Dorne, J et al. Social stress and the reactivation of latent herpes simplex virus type 1. Proc Natl Acad Sci U S A 1998;95:72317235.Google Scholar
43Glaser, R, Rice, J, Sheridan, J et al. Stress‐related immune suppression: health implications. Brain Behav Immun 1987;1:720.Google Scholar
44Glaser, R, Pearson, GR, Bonneau, RH et al. Stress and the memory T‐cell response to the Epstein‐Barr virus in healthy medical students. Health Psychol 1993;12:435442.Google Scholar
45Glaser, R, Pearl, DK, Kiecolt‐Glaser, JK et al. Plasma cortisol levels and reactivation of latent Epstein‐Barr virus in response to examination stress. Psychoneuroendocrinology 1994;19:765772.Google Scholar
46Glaser, R, Kiecolt‐Glaser, JK, Bonneau, RH et al. Stress‐induced modulation of the immune response to recombinant hepatitis B vaccine. Psychosom Med 1992;54:2229.Google Scholar
47Jabaaij, L, Grosheide, PM, Heijtink, RA et al. Influence of perceived psychological stress and distress on antibody response to low dose rDNA hepatitis B vaccine. J Psychosom Res 1993;37:361369.Google Scholar
48Black, PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002;16:622653.Google Scholar
49Dantzer, R. Cytokine‐induced sickness behavior: where do we stand? Brain Behav Immun 2001;15:724.Google Scholar
50Dantzer, R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005;30:947952.Google Scholar
51Anisman, H, Merali, Z, Hayley, S. Sensitization associated with stressors and cytokine treatments. Brain Behav Immun 2003;17:8693.Google Scholar
52Tilders, FJ, Schmidt, ED. Cross‐sensitization between immune and non‐immune stressors. A role in the etiology of depression? Adv Exp Med Biol 1999;461:179197.Google Scholar
53Tuglu, C, Kara, SH, Caliyurt, O et al. Increased serum tumor necrosis factor‐alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170:429433.Google Scholar
54Sutcigil, L, Oktenli, C, Musabak, U et al. Pro‐ and anti‐inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396.Google Scholar
55Gabbay, V, Klein, RG, Guttman, LE et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol 2009;19:423430.Google Scholar
56Rief, W, Pilger, F, Ihle, D et al. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Research 2001;105:165174.Google Scholar
57Tunca, Z, Fidaner, H, Cimilli, C et al. Is conversion disorder biologically related with depression? a DST study. Biol Psychiatry 1996;39:216219.Google Scholar
58Tunca, Z, Ergene, U, Fidaner, H et al. Reevaluation of serum cortisol in conversion disorder with seizure (pseudoseizure). Psychosomatics 2000;41:152153.Google Scholar
59Bakvis, P, Spinhoven, P, Giltay, EJ et al. Basal hypercortisolism and trauma in patients with psychogenic nonepileptic seizures. Epilepsia 2010;51:752759.Google Scholar
60Van Westerloo, DJ, Choi, G, Lowenberg, EC et al. Acute stress elicited by bungee jumping suppresses human innate immunity. Mol Med 2011;17:180188.Google Scholar
61Waage, A, Bakke, O. Glucocorticoids suppress the production of tumour necrosis factor by lipopolysaccharide‐stimulated human monocytes. Immunology 1988;63:299302.Google Scholar
62Briegel, J, Jochum, M, Gippner‐Steppert, C et al. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001;12(Suppl. 17):S70S74.Google Scholar
63Barnes, PJ. Anti‐inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94:557572.Google Scholar
64Dhabhar, FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation 2009;16:300317.Google Scholar